This clinical research study is looking for adults 18 years of age and older who have been diagnosed with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The investigational study drug is a treatment that uses your own immune cells, called T cells, and modifies them into chimeric antigen receptor (CAR) T cells called JCAR017. CAR T cell therapy with JCAR017 may help treat your cancer.
The purpose of TRANSCEND CLL 004 is to evaluate the anti-cancer activity, safety, and tolerability of JCAR017 in patients with relapsed or refractory CLL/SLL. Individuals will be evaluated to determine their eligibility to participate. Each person who qualifies will receive the investigational study drug, study-related medical exams, and study-related laboratory tests at no cost.About CLL and SLL
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are the same cancer but they occur in two different areas of the body: in the blood and bone marrow and in the lymph nodes, respectively. This cancer affects the lymphocytes, which are a type of immune cell that helps the body fight infection. Without the ability to develop healthy lymphocytes, those with CLL or SLL are left at higher risk of infection and illness.
Right now, research is underway on an investigational study drug to see if it may treat your CLL/SLL. And you may be able to take part, if you qualify.About the investigational study drug and CAR T cell therapy
CAR T cell therapy is a new and innovative cancer treatment that makes use of the body’s own cells to help fight cancer. Through a process called leukapheresis, some of your T cells (a type of immune cell) are collected and sent to a manufacturing facility. When your cells are at the facility, they are modified with a gene to help your body recognize and attack cancer cells. This new therapy is called JCAR017, and it is the investigational study drug in TRANSCEND CLL 004.
Participation in the study lasts approximately 26 months. This includes:
The investigational study drug used in TRANSCEND CLL 004 is called JCAR017. This drug is the result of a modification to a participant’s own immune cells (T cells) with a chimeric antigen receptor (CAR). These modified T cells (CAR T cells), may target and reduce the number of cancer cells, which then could provide an environment for healthy cells to grow normally. JCAR017 is administered once as an infusion during the treatment period.